Detail akcie Veracyte online

Business Summary: Veracyte, Inc. is a global diagnostics company. It enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA laboratories in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Veracyte Inc revenues increased 22% to $361.1M. Net loss increased from $36.6M to $74.4M. Revenues reflect United States segment increase of 27% to $334.5M. Higher net loss reflects Research and development - Balancing increase of 50% to $51.1M (expense), General & Administrative Expenses increase of 16% to $66.2M (expense).